drugset
drugset / Trial / NCT01524692

Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma

NCT01524692 ↗

Phase 2 Completed 35 enrolled University of Virginia Novartis Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to improve survival of patients with recurrent or metastatic Adenoid Cystic Carcinoma (ACC). This study will test the efficacy of the investigational drug, TKI258, in treating ACC.

Timeline

Start
2012-03
Primary completion
2014-01
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Dovitinib Small molecule 500 mg Oral

Indications

adenoid cystic carcinoma